Daniel He

Daniel Daniel is a Senior Scientist at Merck, leading the development and execution of in vitro modeling for heart failure and cardiometabolic diseases since September 2022. Prior to this role, Daniel served as a Senior Associate Scientist at Amgen, contributing significantly to early discovery programs using human stem cells and high content imaging. Additionally, a consultancy role at Biotech Connection - Bay Area, Inc. involved strategic market analysis for a next-generation sequencing platform in oncology. Earlier experience includes positions as a Research Associate at The Gladstone Institutes, where Daniel specialized in ChIP-seq and characterized cardiac disease models, and as a Staff Research Associate at UC Berkeley, collaborating on the modENCODE project. Daniel began research career as an intern at UC Davis, focusing on epigenetics in cultured human embryonic kidney cells. Educational achievements include a PhD in Developmental and Stem Cell Biology from the University of California, San Francisco, and a Bachelor of Science in Biotechnology from the University of California, Davis.